Japan’s Drug Maker M&A Activity Expected To Continue Record Pace
This article was originally published in PharmAsia News
The already recording-setting mergers and acquisitions by Japanese companies, including drug makers, is expected to continue as others seek to add to foreign holdings. The companies of the second-largest economy in the world are expected to take advantage of the credit crisis around the world, according to industry insiders. Together, Japanese firms so far this year have made acquisitions worth a combined $47.1 billion, well over the previous record covering all of 2006. Besides Japanese pharmas, makers of auto parts and financial firms are expected to lead the M&A activity. (Click here for more
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.